drugset / Trial / NCT05781360
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
Phase 1
Terminated
192 enrolled
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd. · collabSimcere Zaiming · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, phase I study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic(PD) characteristics of SIM0237 in participants with advanced solid tumors.
Timeline
- Start
- 2023-03-08
- Primary completion
- 2024-05-25
- Completion
- 2024-05-25
Outcome
Outcome not reported
Stopped (Business): “An internal business decision, not based on safety or regulatory considerations.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SIM0237 | Unknown | — | Intravenous |
Indications
No indication recorded.